Allogene Therapeutics (ALLO) Liabilities and Shareholders Equity (2018 - 2026)

Allogene Therapeutics' Liabilities and Shareholders Equity history runs 9 years deep, the most recent figure standing at $396.0 million for Q1 2026.

• In Q1 2026, Liabilities and Shareholders Equity fell 22.05% year-over-year to $396.0 million; the TTM figure through Mar 2026 stood at $1.7 billion (down 24.88% YoY), while the FY2025 annual figure was $415.9 million, down 24.2% from the prior year.
• Liabilities and Shareholders Equity came in at $396.0 million for Q1 2026 at Allogene Therapeutics, down from $415.9 million in the prior quarter.
• In the past five years, Liabilities and Shareholders Equity ranged from a high of $978.1 million in Q1 2022 to a low of $396.0 million in Q1 2026.
• A 5-year average of $654.7 million and a median of $642.8 million in 2023 frame the typical range for Liabilities and Shareholders Equity.
• On a YoY basis, Liabilities and Shareholders Equity climbed as much as 13.37% in 2025 and fell as far as 27.25% in 2025.
• Allogene Therapeutics' Liabilities and Shareholders Equity stood at $821.6 million in 2022, then slipped by 21.76% to $642.8 million in 2023, then retreated by 14.64% to $548.7 million in 2024, then dropped by 24.2% to $415.9 million in 2025, then retreated by 4.8% to $396.0 million in 2026.
• According to Business Quant data, Liabilities and Shareholders Equity over the past three periods registered $396.0 million, $415.9 million, and $439.8 million for Q1 2026, Q4 2025, and Q3 2025 respectively.

Peer Comparison